The efficacy of chemoimmunotherapy in KRAS mutant NSCLC was also analyzed retrospectively in the participants of another randomized trial, the KEYNOTE-189 study of pembrolizumab plus pemetrexed and platinum chemotherapy vs placebo plus chemotherapy as first-line therapy for metastatic non-squamous NSCLC (80). This evidence concerns the gene KRAS and non-small cell lung carcinoma.